论文部分内容阅读
突变的ｒａｓ２１蛋白常发生单个氨基酸置换而成为肿瘤特异性抗原。作者对胰腺癌、结肠癌患者是否存在着对突变ｒａｓ癌基因蛋白特异的Ｔ细胞或抗体进行了临床研究。首先采用ＥＬＩＳＡ法检测了１６０例结肠癌患者及４０例正常对照者血清中是否存在抗ｒａｓＤ１２抗体。抗体检测结果显示：３１．８％病人血清可检出抗ｒａｓＤ１２蛋白的ＩｇＡ抗体，而正常对照组仅１例阳性，占２．５％。结肠癌病人血清中抗ｒａｓＤ１２抗体明显高于正常组，说明突变ｒａｓ癌基因蛋白可诱导机体产生相应抗体反应。进一步采用３Ｈ－ＴｄＲ掺入法检测１６例胰腺癌、２８例结肠癌及１１例正常人外周血中是否存在对突变ｒａｓ蛋白和多肽片段致敏的Ｔ细胞。结果显示，４３．７％胰腺癌病人Ｔ细胞对突变ｒａｓＤ１２多肽呈阳性反应，而１１例正常人则完全阴性。对４例对突变ｒａｓＤ１２多肽呈阳性反应的胰腺癌患者进一步检测其Ｔ细胞能否同时对突变ｒａｓＤ１２蛋白有特异识别，结果３例患者Ｔ细胞能同时对突变ｒａｓＤ１２多肽和蛋白呈阳性反应。１１例正常对照同样对突变ｒａｓＤ１２蛋白无反应。在结肠癌病人中，其Ｔ细胞对ｒａｓＤ１２多肽反应者为８．０％（２／２５）。实验结果表明，突变ｒａｓ蛋白的突变片段具免疫?
The mutated ras21 protein often undergoes a single amino acid substitution and becomes a tumor-specific antigen. The authors conducted a clinical study of the presence or absence of ras oncogene-specific T cells or antibodies in pancreatic and colon cancer patients. Firstly, ELISA was used to detect the presence of anti-rasD12 antibodies in the serum of 160 patients with colon cancer and 40 normal controls. The results of antibody detection showed that 31.8% of patients’ serum could detect IgA antibodies against rasD12 protein, while only 1 case of normal control group was positive, accounting for 2.5%. The anti-rasD12 antibody in the serum of patients with colon cancer was significantly higher than that in the normal group, indicating that the mutant ras oncogene protein can induce the body to produce the corresponding antibody response. Further 3H-TdR incorporation assay was used to detect the presence of T cells sensitized to mutant ras protein and polypeptide fragments in 16 cases of pancreatic cancer, 28 cases of colon cancer, and 11 cases of normal human peripheral blood. The results showed that 43.7% of pancreatic cancer patient T cells were positive for the mutant rasD12 polypeptide, whereas 11 normal people were completely negative. In addition, four cases of pancreatic cancer positive to mutant rasD12 polypeptides were further tested for their ability to specifically recognize the mutant rasD12 protein simultaneously. As a result, T cells in three cases were positive for the mutant rasD12 polypeptide and protein. Eleven normal controls also did not respond to the mutant rasD12 protein. In patients with colon cancer, their T-cell response to rasD12 polypeptide was 8.0% (2/25). The experimental results show that the mutant fragment of the mutant ras protein is immune?